K Ray Chaudhuri, MD, DSc, FRCP, FEAN, King’s College London, London, UK, discusses the use of precision medicine in Parkinson’s disease (PD). There are exciting developments in clinical trials on the genomic side, such as the role of ambroxol in people with GBA mutations. However, precision medicine goes beyond targeted treatment, also considering how best to personalize management based on individual needs. Treatment adjustments can be made based on age and specific symptoms, such as avoiding certain drugs for patients with osteoporosis or memory issues. Prof. Chaudhuri mentions
the Parkinson’s ‘vitals dashboard’ that tracks key symptoms such as vision, gut, and oral health, which may help to target therapies to specific Parkinson’s phenotypes. He believes it’s time to use these advances and run more global trials to better implement precision medicine. This interview took place at the 18th Annual Congress on Controversies in Neurology (CONy 2024) in London, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
